Corporate Banner
Satellite Banner
Technology Networks Header
Tuesday, July 22, 2014
 
Register | Sign in
Home Page > Application Notes
  Application Notes
Scientific News
Transplanting Gene into Injured Hearts Creates Biological Pacemakers
Researchers develop first minimally invasive gene therapy procedure to treat heart rhythm disorders by transforming ordinary heart muscle cells into specialized rhythm-keeping cells, potentially eliminating future need for electronic pacemakers.
Common Gene Variants Account for Most Genetic Risk for Autism
Roles of heritability, mutations, environment estimated - NIH-funded study.
Using LC-MS to Analyse Sulfonamides in Food Grade Honey
Sulfonamides are one of a number of groups of chemicals whose presence in honey is limited by international regulations.
ChIP Sequencing Kit for Next Generation Sequencing
The assay kit from Porvair Sciences extends the benefits of their proprietary Chromatrap® solid state ChIP technology.
Illumina's HiSeq X Ten Sequencing Technology for Population Studies
Next-generation sequencing technologies to be implemented at new High-Throughput Genomics Center for the MENA region.
Foodborne Pathogen Detection Speeds Up Dramatically
Next-generation sequencing techniques allow rapidly identification of strains of salmonella, quickening responses to potential outbreaks.
Bowel Cancer Breakthrough May Benefit Thousands of Patients
Researchers at Queen’s University have discovered how two genes cause bowel cancer cells to become resistant to treatments used against the disease.
Innovative Technology Enables First Crystal Structure of mGlu5 Transmembrane Domain to be Determined
Several novel drug candidates have been identified to help treat specific neuropsychiatric disorders.
NIH Scientists Identify Gene Linked to Fatal Inflammatory Disease in Children
Repurposed drugs may offer first potential therapy.
Replace Reduce Refine
A way forward for antibiotic use in agriculture.
Scroll Up
Scroll Down

Efficient Delivery of Thermo Scientific Dharmacon SMARTpool siRNA Reagents in Difficult-to-Transfect Cell Lines Using Nucleofector® 96-well Shuttle® System
Bookmark and Share
Lonza


For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



Lonza and BioWa Sign Licensing Agreement with MedImmune
MedImmune has licensed Potelligent® CHOK1SV Cell Line Technology to both Companies.
Monday, December 16, 2013
Lonza and Hyglos Reach Agreement for Endotoxin Detection Patents
Agreement allows Hyglos to use recombinant factor C technology to produce its own endotoxin products.
Friday, March 15, 2013
Lonza to Expand ADC Manufacturing Capacity
Capacity expansion is expected to be complete in the second quarter of 2014.
Thursday, January 10, 2013
Lonza and Agennix Sign Development and Manufacturing Deal for Production of Talactoferrin
Lonza will manufacture talactoferrin at its microbial facility in Kourim, Czech Republic.
Thursday, April 19, 2012
Lonza Appoints Richard Ridinger as New CEO
Board of Directors elects Mr. Ridinger at a meeting on 2 April 2012.
Thursday, April 05, 2012
Lonza Expands Singapore Bioservices
The expansion will support cell line construction, upstream and downstream process development, and a broad range of analytical services.
Monday, June 13, 2011
Lonza Selects IDBS to Optimize Bioprocess Execution & Knowledge Management
Lonza has chosen IDBS to provide an electronic data management and execution solution for mammalian cell culture process development. Lonza will deploy IDBS's Bioprocess Execution System to optimize the management of process development data and drive operational excellence.
Wednesday, January 05, 2011
Lonza Acquires Viral Vaccine and Vector Manufacturer Vivante GMP Solutions
Lonza expands its custom service platform to viral vaccines and gene therapy vectors.
Tuesday, August 31, 2010
Elusys Therapeutics and Lonza Enter Into Manufacturing Agreement
Lonza provides process development services and manufacturing capacity for this product using Lonza's GS Gene Expression System™.
Wednesday, June 17, 2009
Lonza Initiates Large Scale Production Capacity and Technology Platform for Antibody Drug Conjugates
Lonza plans to start large scale production of emerging product class Antibody Drug Conjugates to be utilized primarily in the treatment of cancer.
Friday, May 18, 2007
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv